Longeveron to Participate in Three Longevity/Aging Investment Conferences
Globe Newswire•30/09/2026•16:05 ET
0
Key Highlights
- ➤$1,000,000 Milestone 2 Award received from XPRIZE Healthspan competition
- ➤Up to $81 million Grand Prize opportunity remains in XPRIZE Healthspan competition
- ➤Phase 2b trial showed laromestrocel improved age-related frailty after nine months
- ➤Phase 2a Alzheimer’s analysis indicated reduced neuroinflammation, but remains pre-peer review
- ➤Longeveron (LGVN) will pursue funding and revenue opportunities for laromestrocel
MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.
13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston
Get started
Create a free account to read the full story.